The most recent FDA approval belongs to BCG plus N-803, which has an initial complete response of 62%, falling to just 36% at 12 months. For technologies currently under clinical evaluation, ...
In this Comment, Ben-Aharon et al. advocate for the creation of designated OncoYoung programs to address the unique needs of individuals with early-onset cancer, as well as multinational platforms ...
Elekta Evo, our latest AI-powered adaptive CT-Linac and Elekta ONE Planning has been launched at ASTRO and, in the quarter, also at ASTRO in Washington. Customer feedback has been very encouraging and ...